Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q3 2022 · 10-Q
Revenue$7.01M$7.01M+482.5% vs Q3 2021 Net Income-$41.42M-$41.42MN/M vs Q3 2021 EPS Diluted-$0.04-$0.04N/M vs Q3 2021 Operating Income-$42,990,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$58,166,000N/M Margins · derivedOperating margin-613.5%+2892.8 pt vs Q3 2021
Net margin-591.1%+2933.5 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 8, 2022 · 39 d after period end